-+ 0.00%
-+ 0.00%
-+ 0.00%

Zymeworks to present Phase 1 ZW191 dose-escalation data at AACR 2026

PUBT·04/17/2026 19:00:36
Listen to the news
Zymeworks to present Phase 1 ZW191 dose-escalation data at AACR 2026
  • Zymeworks flagged updated results from Part 1 dose escalation of Phase 1 ZWI-ZW191-101 trial of ZW191 in advanced solid tumors for oral presentation at AACR on April 21, 2026.
  • Early study readout is positioned to inform dose selection and next-step development for ZW191, an FRα-targeted antibody-drug conjugate.
  • Separately, six AACR posters already outline new preclinical findings across Zymeworks’ antibody-drug conjugate pipeline, including tumor-selective delivery claims for a pan-RAS inhibitor ADC platform.
  • Preclinical updates highlight broad anti-tumor activity across solid tumor models with tolerability described as supportive of continued development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604171500OMX_____CNEWS_EN_GNW9691757_en) on April 17, 2026, and is solely responsible for the information contained therein.